PATENT CLAIM ANALYSIS

Application Number: 15781156
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["435", "006110"]

Abstract:
The present invention relates to a RET fusion gene such as a CCDC6-RET fusion gene as a biomarker to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments. The present invention also relates to specific uses of said specific compound in the treatment of cancers.

Claim (Index 9):
The method of  claim 1 , wherein said RET fusion gene is CCDC6-RET, and wherein said RET fusion gene product is the product of the CCDC6-RET fusion gene.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 94.0
- Lexical Diversity: 1.5
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12720663', '14429834', '15130486', '14187280', '15590487']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6057350055673668
- 35 USC 102 Novelty (BERT): 0.4955899245499592
- Combined Prediction Score: 0.594720497465626
- Mean Citation Score: 217.351282
- Max Citation Score: 270.6839
- Similarity Product: 227.74288919534683

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test